

New

Alfaxan® Multidose

Alfaxalone Injection 10 mg/mL

The consistency and confidence you have developed with Alfaxan now comes in a **multidose** vial.



Preserved formulation allows for 28 day shelf-life after broaching



Repeatable and reliable anesthesia provides for smooth inductions



Helps maintain clinically acceptable cardiovascular and respiratory parameters



Rapid clearance and recovery



day shelf life
after broaching

**AVAILABLE NOW in BOTH
10 mL and 20 mL vials!**



CSL Code	VP	CDMV	DESCRIPTION
424-520415	1401310	126169	Alfaxan Multidose 10 mL
424-520425	1401315	126452	Alfaxan Multidose 20 mL



Master Distributor for Canada
Central Sales Limited
Toll free 1-800-387-2522



Distributor Partner
Pacific Veterinary Sales
Toll free 1-800-663-6966

www.jurox.ca

Repeatable. Reliable. Relax.



© Registered Trademark of Jurox Pty Ltd

Alfaxan Multidose is the new, preserved formulation of alfaxalone, combining the reliability you have come to expect from **Alfaxan**, with the versatility that comes with an extended shelf life of 28 days after first opening.

SAFETY MARGIN

ADMINISTER
OVER



pH neutral = No tissue irritation
formulation irritation

10×

5×




USE WITH CONFIDENCE

- ✓ Helps maintain clinically acceptable cardiovascular and respiratory parameters
- ✓ Versatility from healthy to special populations to compromised patients. (ASA I-V¹, C-Sections², sighthounds³, brachycephalic⁴, juvenile cat and dogs⁵)
- ✓ Compatible with commonly used premedicant, maintenance and analgesic protocols


BIOEQUIVALENCE ALFAXAN VS ALFAXAN MULTIDOSE



Plasma alfaxalone concentration vs time in dogs treated with Alfaxan or Alfaxan Multidose at 3 mg/kg (n=24 per group).



Plasma alfaxalone concentration vs time in cats treated with Alfaxan or Alfaxan Multidose at 5 mg/kg (n=24 per group).



References:

- [Graphs] Jurox GLP study JX9604.08-L026 – An in vivo study investigating the bioequivalence of Alfaxan® versus alfaxalone plus preservatives as an injectable anesthetic agent in dogs. Paslosk K et al. The bioequivalence of a single intravenous administration of the anesthetic alfaxalone in cyclodextrin versus alfaxalone in cyclodextrin plus preservatives in cats. J Vet Pharmacol Ther 2018 Jan 19. doi: 10.1111/jvp.12485 [Epub ahead of print].
1. Psatha E, et al., Clinical efficacy and cardiorespiratory effects of alfaxalone, or diazepam/fentanyl for induction of anaesthesia in dogs that are a poor anaesthetic risk. Vet Anaesth Analg, 2011, 38: p. 24-36.
 2. Metcalfe, S. et al., Multicentre, randomised clinical trial evaluating the efficacy and safety of alfaxalone administered to bitches for induction of anaesthesia prior to caesarean section. Aust Vet Journal, Vol. 92, No 9, Sept 2014: p. 333-338.
 3. Pasloske, K., et al., Plasma pharmacokinetics of alfaxalone in both premedicated and unpremedicated Greyhound dogs after single, intravenous administration of Alfaxan at a clinical dose. J. vet. Pharmacol. Therap. 32, 510-513
 4. Jurox report, JX9604.03-C009 (GCP), Dog Field Trial
 5. O'Hagan, B., et al., Clinical evaluation of alfaxalone as an anaesthetic induction agent in dogs less than 12 weeks of age. Aust. vet. Journal, 2012, 90(9): p. 344-50.
 5. O'Hagan, B., et al., Clinical evaluation of alfaxalone as an anaesthetic induction agent in cats less than 12 weeks of age. Aust. vet. Journal, 2012, 90(10): p. 395-401



© Registered Trademark of Jurox Pty Ltd

Master Distributor for Canada
Central Sales Limited
Toll free 1-800-387-2522

Distributor Partner
Pacific Veterinary Sales
Toll free 1-800-663-6966

www.jurox.ca